
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
With one in four children at risk for becoming overweight and one in 10 children already overweight, childhood obesity is an epidemic fast becoming a national health problem.






